focus -WSS

focus

author：comprehensive 2025-09-03 09:38:26 - browse：491

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

WSS

Redefining sustainability for the pharmaceutical industry

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

CVS Caremark has created a new ploy: the drug ‘rebate credit’

5 ways to address the shortage of health care workers

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

CVS Caremark has created a new ploy: the drug ‘rebate credit’

knowledge

focus

hotspot

Guidelines to prevent youth baseball injuries need more muscle

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Sports medicine is finally prioritizing gender equality

Health AI adoption puts security, privacy startups on investors' radar

Continuity nursing helped my family in our darkest PICU moments

Creating egg and sperm cells from stem cells raises ethical issues

Novavax promises a turnaround & Lilly roils the obesity market

Creating egg and sperm cells from stem cells raises ethical issues

Duchenne breakthrough therapy leaves behind pioneering families

STAT Madness 2024: Meet the contenders

hotspot

Asbestos, a deadly carcinogen, banned by EPA

Creating egg and sperm cells from stem cells raises ethical issues

CVS Caremark has created a new ploy: the drug ‘rebate credit’

CDC advisory group OKs chikungunya vaccine

STAT Madness 2024: Meet the contenders

Intermittent fasting comes with a heart risk? Not so fast

leisure time

Wikipedia

focus

explore